IL31 and systemic sclerosis: As blocking IL-31/IL-31RA has been shown to reduce cytokine release and fibrosis in SSc patients and IL-31/IL-31RA is overexpressed in patient dermal fibroblasts, this mediator may be a therapeutic target [92].